Calliditas Therapeutics AB (publ)
CALT
NASDAQ
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Net Income | -4.44M | -23.68M | -1.73M | -15.58M | -8.74M |
| Total Depreciation and Amortization | -- | -- | 1.56M | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 6.81M | 3.30M | 4.96M | 4.23M | -2.05M |
| Change in Net Operating Assets | -3.03M | 1.31M | -2.64M | 5.57M | -4.71M |
| Cash from Operations | -658.80K | -19.07M | 2.15M | -5.79M | -15.49M |
| Capital Expenditure | -- | -- | -1.20M | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -9.50K | -371.20K | 981.30K | -686.40K | -100.70K |
| Cash from Investing | -9.50K | -371.20K | -221.40K | -686.40K | -100.70K |
| Total Debt Issued | -- | -- | 962.89M | -- | -- |
| Total Debt Repaid | -4.06M | -5.47M | -727.74M | -2.89M | -3.02M |
| Issuance of Common Stock | 14.00K | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -26.63M | -- | -- |
| Cash from Financing | -378.40K | -526.00K | 19.61M | -267.30K | -286.50K |
| Foreign Exchange rate Adjustments | -172.90K | 4.24M | -3.97M | -598.20K | 1.87M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -100.00 | -- | -100.00 |
| Net Change in Cash | -1.22M | -15.72M | 17.57M | -7.34M | -14.01M |
